Financials

Q1progresspositions Abbott for accelerating growthin 2026

2025 results: Abbott achieves double-digit earnings growth

Our legacy of dividend growth continues

Abbott delivers strong Q3 results, reaffirms 2025 outlook

Pacing ahead: AVEIR pumps new life into CRM business

Abbott's diversified healthcare leadership fuels Q2 results

Abbott Delivers Top-Tier Q1 Sales and EPS Growth

Inside Abbott’s Largest Business: Spotlight on Medical Devices

Favorable demographics propel growth in adult nutrition

Q4 Momentum Positions Abbott for Strong Growth in 2025

Abbott Increases Dividend For 53rdConsecutive Year

Abbott Opens New Facility To Meet Demand For Diabetes Technology

Structural Heart’s Steady Beat of Innovation and Impact

Strong Performance by Abbott’s Base Business Drives Q3 Earnings

Report Finds Abbott is Most Profitable Healthcare Stock of All Time

Abbott Q2: Strong Base Business Growth Continues

Innovating for a Healthier, Sustainable Future

Abbott Enters U.S. Consumer Biowearables Market With Lingo and Libre Rio

Abbott’s Momentum Continues in First Quarter of 2024

Abbott’s TriClip Offers New Treatment Option for People With Tricuspid Regurgitation

Abbott’s Q4 Earnings Sustain Momentum Into 2024

A New Chapter in FreeStyle Libre Technology

Continuing to Lead the Way in Sustainability

Base Business Strength Accelerates Abbott’s Growth

Abbott Raises Dividend for 52nd Consecutive Year

Benefits of Using FreeStyle Libre With GLP-1 Therapy

Abbott's Q3 Continues Underlying Base Business Growth Driven by Pandemic Investments

Abbott Leaders Take Center Stage at HLTH Conference

Findings from our FreeStyle Libre/GLP-1 Analysis

Base Business Powers Abbott’s Second-Quarter Results

Shaping the Future of Abbott, Healthcare

Abbott Delivers Q1 Results

Abbott Q4 Earnings: Continued Resiliency

The Partnerships Changing How You Manage Diabetes

Meet Navitor: Key Add to Structural Heart Portfolio

Poised for Growth Amid Uncertain Environment

Abbott's Dividend Payout Continues to Grow

Abbott’s biowearable: One sensor for glucose, ketones

FreeStyle Libre 3: Welcome to the U.S.

Abbott Levels-Up Wireless Pacemaker Tech

Innovations Born from the Pandemic have only just Begun

CardioMEMS Set for Broader Use

50 Years of Dividend Growth

Flu, Meet COVID-19: What to Know About This Season

Why This Health Tech Leader is Built to Last

Science, Real Madrid Team Up for Global Health Win

Structural Heart Portfolio Reaches New Heights

ABBOTT Q2 EARNINGS: EXCEPTIONAL PERFORMANCE & MOMENTUM

The future of connected health tech is here

Rising to the Test, Innovating for the Future

Connected Tech Making Diabetes Management Easier

Innovating with Resilience

Abbott's diversified business portfolio pays off

MitraClip Set for Significantly Broader Use

Resilience in a Time of Disruption

COVID-19: Inspiring the Future of Testing

Abbott's Tests Helping Tackle the Pandemic

FreeStyle Libre 3: World's Smallest Sensor is Here

Reskilling: A Key to Abbott's Success

COVID-19 Testing is Needed on a Mass Scale

Freestyle Libre 2: Next-Gen CGM is Here

Abbott Adds to Structural Heart Tech

Game-Changing News for Heart Health

Improving Health Through Better Data

Abbott Brings Its Proven Flu Fighters

A Better Way to Put 2 and 2 Together

Abbott Reports Full-Year 2018 Results

How Modern Healthcare Is Transforming

Rapid Diagnostics Builds for Its Future

Delivering Accurate Results Faster Than Ever

From Start-up to Success Story

St. Jude Medical Is Now Abbott